Analyzing Patheon N.V. (PTHN) and Its Rivals
Patheon N.V. (NYSE: PTHN) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Patheon N.V. to similar businesses based on the strength of its earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Institutional and Insider Ownership
12.2% of Patheon N.V. shares are held by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.1% of Patheon N.V. shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Patheon N.V. has a beta of 3.06, suggesting that its share price is 206% more volatile than the S&P 500. Comparatively, Patheon N.V.’s competitors have a beta of 36.48, suggesting that their average share price is 3,548% more volatile than the S&P 500.
This table compares Patheon N.V. and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Patheon N.V. Competitors||-2,399.97%||-68.06%||-7.34%|
Earnings and Valuation
This table compares Patheon N.V. and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Patheon N.V.||$1.87 billion||$31.70 million||46.64|
|Patheon N.V. Competitors||$8.17 billion||$1.09 billion||127.97|
Patheon N.V.’s competitors have higher revenue and earnings than Patheon N.V.. Patheon N.V. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent recommendations and price targets for Patheon N.V. and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Patheon N.V. Competitors||863||3777||6746||179||2.54|
Patheon N.V. currently has a consensus target price of $33.60, suggesting a potential downside of 3.95%. As a group, “Pharmaceuticals” companies have a potential upside of 22.38%. Given Patheon N.V.’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Patheon N.V. has less favorable growth aspects than its competitors.
Patheon N.V. competitors beat Patheon N.V. on 10 of the 13 factors compared.
About Patheon N.V.
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.
Receive News & Stock Ratings for Patheon N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon N.V. and related stocks with our FREE daily email newsletter.